Cargando…

Bringing circulating tumor DNA to the clinic in Hodgkin lymphoma

Detalles Bibliográficos
Autor principal:	Kurtz, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776242/ https://www.ncbi.nlm.nih.gov/pubmed/33386712 http://dx.doi.org/10.3324/haematol.2020.265165

Ejemplares similares

Circulating tumor DNA in Hodgkin lymphoma
por: Maco, Maria, et al.
Publicado: (2022)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Immunotherapies in Non-Hodgkin’s Lymphoma
por: Bezombes, Christine, et al.
Publicado: (2021)

Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study
por: Camus, Vincent, et al.
Publicado: (2020)

S236: HIGH-BREADTH SEQUENCING OF CIRCULATING TUMOR DNA IDENTIFIES NOVEL CLASSIFICATION OF HODGKIN LYMPHOMA
por: Heger, Jan-Michel, et al.
Publicado: (2023)

Advances and Clinical Outcomes in Hodgkin Lymphoma in the Era of Novel Therapies
por: Paviglianiti, Annalisa, et al.
Publicado: (2023)

Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma
por: Primerano, Simona, et al.
Publicado: (2016)

Second cancer risk following Hodgkin lymphoma
por: Sud, Amit, et al.
Publicado: (2017)

Editorial bring in the new!
por: Glover, David M.
Publicado: (2016)

Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab
por: Shi, Yuankai, et al.
Publicado: (2020)

Progress in understanding the biology of nodular lymphocyte-predominant Hodgkin lymphoma
por: Straus, David J.
Publicado: (2021)

A race to bring CRISPR to the clinic
Publicado: (2017)

Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
por: Bari, Alessia, et al.
Publicado: (2022)

Managing advanced stage Hodgkin lymphoma
por: Saikia, TK
Publicado: (2015)

Expanding the bacterial origins of nodular lymphocyte-predominant Hodgkin lymphoma
por: Gandhi, Maher K., et al.
Publicado: (2023)

DNA Methylation of Tumor Suppressive miRNAs in Non-Hodgkin’s Lymphomas
por: Yim, Rita Lok-Hay, et al.
Publicado: (2012)

P1283: CIRCULATING IMMUNE CELLS IN CLASSICAL HODGKIN LYMPHOMA IN RELATION TO TUMOR BURDEN AND TREATMENT
por: Mulder, T. A., et al.
Publicado: (2022)

Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin Lymphoma
por: Ansell, Stephen M.
Publicado: (2017)

DNA content and prognosis of non-Hodgkin's lymphoma.
por: Morgan, D. R., et al.
Publicado: (1986)

Bringing nerve excitability out of the research laboratory into the clinic
por: Ng, Karl
Publicado: (2022)

Circulating Tumor DNA Testing for Liver Cancer
por: Furtado, Larissa V., et al.
Publicado: (2015)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma
por: Mammadova, Laman, et al.
Publicado: (2022)

Bringing Intersectionality to Cardiovascular Health Research in Canada
por: Allana, Saleema, et al.
Publicado: (2021)

Bringing base editing to the clinic: The next generation of genome editors
por: Flugel, Christian L., et al.
Publicado: (2023)

PET-guided treatment in advanced-stage Hodgkin lymphoma: yes but which one?
por: Rossi, Cédric, et al.
Publicado: (2019)

Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma
por: Chiu, Brian C.-H., et al.
Publicado: (2021)

T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
por: Lynch, Ryan C., et al.
Publicado: (2022)

P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
por: Mulder, Tom A., et al.
Publicado: (2022)

Tumor Size Measurements for Predicting Hodgkin’s and Non-Hodgkin’s Lymphoma Response to Treatment
por: Kallergi, Maria, et al.
Publicado: (2022)

Bringing basic and clinical research together to an integrated understanding of psychiatric disorders
por: Ising, Marcus
Publicado: (2007)

Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma
por: Borchmann, Sven, et al.
Publicado: (2018)

CD4 T cells: the complicated key to unlocking the immune environment of classical Hodgkin lymphoma
por: Gandhi, Maher K., et al.
Publicado: (2022)

Hodgkin Lymphoma—The Spectrum from Diagnostics to Molecular Science, Movement and Current Treatment Approaches
por: Hartmann, Sylvia
Publicado: (2023)

Cell-Free DNA for the Management of Classical Hodgkin Lymphoma
por: Camus, Vincent, et al.
Publicado: (2021)

Biostable ssDNA Aptamers Specific for Hodgkin Lymphoma
por: Parekh, Parag, et al.
Publicado: (2013)

Mitochondrial DNA Fragmentation and Risk of Non-Hodgkin Lymphoma
por: Hosgood, H. Dean, et al.
Publicado: (2023)

Circulating Mediators of Inflammation and Immune Activation in AIDS-Related Non-Hodgkin Lymphoma
por: Nolen, Brian M., et al.
Publicado: (2014)

Mentorship: The Bond that Brings Us Together
por: Dunbar, Gary L.
Publicado: (2007)

Bringing neurosurgical and neurological care to the world
por: Cheatham, Melvin L.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s822qjkflkn8imj9cbao12ipqh